United Therapeutics reported $2.88B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Amarin USD 612.88M 10.12M Sep/2026
Ardelyx USD 441.39M 538K Sep/2026
Baxter International USD 6.83B 163M Sep/2026
Bayer EUR 39.6B 5.96B Sep/2026
BioCryst Pharmaceuticals USD 531.15M 46.47M Sep/2026
Biogen USD 7.58B 278.7M Sep/2026
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
Emergent BioSolutions USD 679.5M 41.3M Dec/2023
Gilead Sciences USD 16.55B 4.02B Sep/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
Halozyme Therapeutics USD 1.85B 913.71M Sep/2026
Insmed USD 1.71B 72.59M Sep/2026
Ionis Pharmaceuticals USD 2.36B 129.77M Sep/2026
J&J USD 56.35B 3.42B Sep/2026
Lexicon Pharmaceuticals USD 186.03M 84.14M Mar/2026
Moderna USD 7.34B 1.53B Sep/2026
Omeros USD 69.65M 26.53M Jun/2025
Pfizer USD 45.01B 3.65B Sep/2026
PTC Therapeutics USD 2.54B 79.58M Sep/2026
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sarepta Therapeutics USD 2.27B 49.06M Sep/2026
Teva Pharmaceutical Industries USD 14.6B 842M Sep/2026
United Therapeutics USD 2.88B 603.5M Sep/2026
Vertex Pharmaceuticals USD 11.69B 857.4M Sep/2026